Dr. Ulas Darda Bayraktar, MD

Dr. Bayraktar practices at University Hospitals Geneva Medical Center in Geneva, Ohio, part of University Hospitals Health System.

Dr. Bayraktar's NPI, 1528267952, was assigned on July 16, 2007. Dr. Bayraktar holds West Virginia license 28598.

Dr. Bayraktar's primary practice is University Hospitals Geneva Medical Center, at 870 West Main Street, Geneva, OH 44041 in Ashtabula County. The practice phone is (440) 415-0151.

Dr. Bayraktar's primary practice is University Hospitals Geneva Medical Center in Geneva, Ohio, part of University Hospitals Health System. Dr. Bayraktar is also affiliated with University Hospitals Cleveland Medical Center. The medical group on file is University Hospitals Medical Practices. Dmand AI also links Dr. Bayraktar to 3 more hospitals, 1 breast imaging center, 1 group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Bayraktar practices, 7 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Bayraktar's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Bayraktar's licenses on file in 2 states: West Virginia and Texas.

CMS data shows 391 Medicare services from Dr. Bayraktar across 7 procedure codes in 2024, for 214 Medicare patients. Medicare paid $33,568 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 214 Medicare patients who saw Dr. Bayraktar in 2024. The largest group is 75 to 84, with 89 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 13% are also on Medicaid. Their average risk score is 2.06, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Bayraktar's median patient age at 73, with 60% women.

In 2024, Dr. Bayraktar wrote 421 Medicare Part D claims for 113 patients. 74% of them were for generic drugs. CMS names the drug for 191 of them, across 9 drugs with 11 or more claims each, at $378,261 in total drug cost. In 2023, CMS named 326 claims across 12 drugs.

Dr. Bayraktar accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Bayraktar as offering telehealth.

Dmand AI links 20 papers to Dr. Bayraktar, published from 2010 to 2016. 2011 was the busiest year, with 7. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols, Graft vs Host Disease and Stem Cell Transplantation. Dr. Bayraktar has published most often in Biol Blood Marrow Transplant. Dr. Bayraktar's most frequent co-authors are Richard E. Champlin, MD, Denise L. Pereira, MD and Elizabeth J. Shpall, MD.

CMS Open Payments shows 52 general payments to Dr. Bayraktar from 25 drug and device companies from 2018 to 2025. Food and beverage make up the largest share, 98% of the total. AstraZeneca Pharmaceuticals LP paid the most, $207.